During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnson’s (J&J’s) Simponi and Takeda’s Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively.
Pfizer developed Xeljanz (tofacitinib, formerly known as tasocitinib), an oral, small-molecule JAK inhibitor, for the treatment of RA, and as a potential treatment for psoriasis, psoriatic arthritis, ankylosing spondylitis, CD, and UC. Xeljanz is a potential first-in-class product for UC, being one of the most advanced JAK inhibitors in the pipeline.
Complete report is spread across 59 pages is available @ http://www.reportsnreports.com/reports/282182-xeljanz-ulcerative-colitis-forecast-and-market-analysis-to-2022.html .
